Table 1 |
|
|
Patient characteristics |
|
|
All patients n = 134 |
|
|
|
|
|
Mean age at diagnosis; years (SD) (range) |
63.2 (8.3) (47-80) |
|
|
|
|
Mean follow-up time; years (SD) |
10.1 (3.5) |
|
|
|
|
RF positive (%) |
94/132 (71.2) |
|
|
|
|
Anti-CCP positive (%) |
34/57 (59.6) |
|
|
|
|
Smoking at diagnosis (%) |
39/118 (33.1) |
|
|
|
|
Low formal education (< 8 years of school) (%) |
66/128 (49.3) |
|
|
|
|
Prednisolone at diagnosis (%) |
39/120 (32.5) |
|
|
|
|
Biological treatment ever (%) |
37/133 (27.8) |
|
|
|
|
Number of used DMARDS; median (IQR) |
2 (1-3) |
|
|
|
|
> 3 DMARDs used (%) |
30 (22.4) |
|
|
|
|
DMARDS in combination (%) |
54 (40.3) |
|
|
|
|
Documented radiographic erosions (ever) (%) |
71/125 (56.8) |
|
|
|
|
Severe extraarticular manifestations (%) |
7 (5.2) |
|
|
|
|
Median HAQ at diagnosisa |
0.87 |
|
|
|
|
Median HAQ 1 year after diagnosisa |
0.75 |
|
|
|
|
Median HAQ 5 years after diagnosisa |
0.75 |
|
|
|
|
Median HAQ 10 years after diagnosisa |
0.88 |
|
|
|
|
CCP, cyclic citrullinated peptide; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; IQR, interquartile range; RF, rheumatoid factor; SD, standard deviation. aData available for HAQ at diagnosis in 70 cases, for HAQ at 1 year in 82 cases, for HAQ at 5 years in 92 cases, and for HAQ at 10 years in 63 cases. |
|
|
Pikwer et al. Arthritis Research & Therapy 2012 14:R190 doi:10.1186/ar4021 |
|
